Cite
HARVARD Citation
Fan, L. et al. (2017). Chromogranin A and neurone‐specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration‐resistant prostate cancer. BJU international. pp. 226-232. [Online].